Tag: AstraZeneca

  • FG okays second dose of AstraZeneca vaccine for eligible Nigerians

    FG okays second dose of AstraZeneca vaccine for eligible Nigerians

    Nigeria will begin administering the the second dose of the Oxford-AstraZeneca COVID-19 vaccines on eligible Nigerians who received the first shots.

    Dr Faisal Shuaib, Executive Director of the National Primary Health Care Development Agency (NPHCDA), made this known during the Presidential Steering Committee (PSC) briefing in Abuja.

    Shuaib advised health workers, frontline workers aged 18 years and above and persons aged 50 years and above to visit any designated vaccination site to receive the vaccine free of charge.

    “I want to remind you that the eligibility period between the first and second doses of the vaccine has been expanded from 12 weeks to between six to 12 weeks, in line with the scientific recommendation provided by the World Health Organisation’s Strategic Advisory Group of Experts (SAGE on immunization).

    ”The PSC has approved the second dose of the Oxford-Astrazeneca vaccination in all states of the federation and the FCT.

    “We have redeployed Senior Supervisors to the states and have continued to monitor activities with daily evening review meetings to determine the status of the COVID-19 vaccine implementation in all states and the FCT.

    “These meetings, allows us to receive reports from the sub-national level on how the campaigns are proceeding, what challenges they face, and how we can pro-actively anticipate and resolve any impending challenges.

    ”The meetings also provide an avenue to troubleshoot and resolve any operational hurdles as they emerge, before they become problematic,” he explained.

    He said that as was recorded the polio virus eradication fight, the agency is strengthening the COVID-19 vaccination campaign at community level with Town Hall meetings across the country.

    ”Already we held the North-Central Zonal Town Hall Meeting two weeks ago in Lafia, the capital of Nasarawa state.

    ”In weeks ahead, the agency hopes to continue the dialogue in other geo-political zones of the country.

    “The town hall meetings afford the communities the opportunity to directly participate in dialogue with the government as we work to protect the people against the pandemic.

    “We know that many people are very concerned about the health threats posed by COVID-19, but also about the economic threats.

    ”The meetings allow for views and concerns to be heard as we work together to move beyond COVID-19 as a nation,” he said.

    The NPHCDA boss urged Nigerians to continue to cooperate with vaccinators who were providing an incredibly important service to the nation amid this global crisis.

    He added that the government would ensure that only safe and efficacious vaccines were supplied for all phases of the vaccination campaign in the country.

    “We would like to state our appreciation to the Nigerian citizens for the cooperation they are providing to our vaccination teams across the country.

    ”We are continuing to optimise our registration and immunization data system, to maximize the efficiency of this system.

    “The need to protect ourselves and put COVID-19 behind us, the way we have done to polio, so that we can return to our normal living, truly is a national effort,” he stated.

  • EU contract with AstraZeneca on COVID-19 jabs ends June

    EU contract with AstraZeneca on COVID-19 jabs ends June

    The European Union has not extended a contract for COVID-19 vaccines with British-Swedish manufacturer AstraZeneca, Internal Market Commissioner, Thierry Breton said on Sunday.

    “We have not extended the order beyond the month of June.

    “We will see. We will see what happens,” Breton told French broadcaster France Inter with regards to AstraZeneca.

    AstraZeneca’s COVID-19 vaccine has been linked with a very rare risk of potential blood clots, especially for younger women, resulting in some countries restricting its use to only older age groups.

    Breton expressed a positive view about the quality of AstraZeneca’s shot. “This is a good vaccine,” he said.

    The European Commission on May 8, struck a deal with COVID-19 vaccine producer BioNTech/Pfizer to buy up to 1.8 billion additional doses until 2023.

  • AstraZeneca: Lagos investigating two cases of suspected blood clot

    AstraZeneca: Lagos investigating two cases of suspected blood clot

    The Lagos State Government has said it is investigating two cases of suspected blood clot following vaccination with AstraZenca vaccine in the state.

    Commissioner for Health, Prof. Akin Abayomi disclosed this in a statement while giving update on COVID-19 vaccination in the state.

    According to Abayomi, so far, following the administration of the first dose of the vaccine to 257,756 persons, just a few of the persons vaccinated experienced what is termed adverse events following immunisation (AEFI) or adverse event of special interest (AESI) characterised by pain at the injection site, fever or body pains lasting 24 to 48 hours and anaphylactic shock.

    “We are being extremely diligent for blood coagulation disorders in view of the prevailing international scientific attention to the possibility of increased risk of developing blood clotting disorders and two cases are being investigated.

    “It is important in the interest of scientific knowledge to be able to attribute any blood clotting problems directly to the administration of the vaccine.

    “The Lagos State Government has robust surveillance systems to effectively monitor and track untoward events and I would like to urge anyone who experiences any adverse events to call the number of the LGA Disease Surveillance Notification written in front of the vaccination card so that such cases can be thoroughly investigated and monitored,” he said.

    Abayomi said the government had learnt several lessons during this vaccination drive, and that the challenges encountered would be addressed before the commencement of the administration of the second doses vaccination drive.

    One of the challenges, he said, included the need to perfect the digital platform that would ensure scheduling of clients to prevent overcrowding at the facilities, which led to opportunists taking advantage of chaos that might ensue.

    Another challenge, he added, was continuous active risk communication to manage the expectation of the residents, educate them as to the need to properly monitor adverse events and report them through the official channels.

    “We sincerely apologize to citizens that may have experienced any inconveniences during the first doses administration exercises and we pledge to try to manage the mammoth logistics more effectively moving forward.

    “It is important to reiterate that residents, including vaccinated persons, must continue to adhere to the measures proposed to curb the spread of the virus, i.e. wearing of face masks in public, social distancing, avoidance of crowded areas, frequent washing of hands and practice of good respiratory hygiene.

    “Lagos State is fully aware of the evolution and global circulation of COVID-19 virus mutant and variant strains that appear to be acquiring the ability to cause multiple waves characterized by more serious clinical outcomes in countries like India, Brazil and certain parts of Europe,” he stated.

    He said Lagos State. the consistent epicenter of Nigeria, had come out of the second wave successfully, but noted that the government is not relaxing on its oars and is preparing assiduously for all eventualities. Mr. Governor is committed to achieve herd immunity for its population through the vaccination exercise.

  • No fewer than 1.13m AstraZeneca shots administered – NPHCDA

    No fewer than 1.13m AstraZeneca shots administered – NPHCDA

    No fewer than 1.13 million shots of AstraZeneca COVID-19 vaccines have been administered across the 36 States of the Federation and the FCT.

    The National Primary Health Care Development Agency (NPHCDA) made this known on its official Twitter handle on Wednesday.

    “As of April 21, 1, 133, 325 representing 56.3 per cent of the eligible persons targeted with the AstraZeneca vaccine have been administered with their first dose in this vaccination phase,” it said.

    The agency said that Lagos state topped the list by 218, 174 shots while Kano, administered 59,040.

    It is followed by Kaduna – 58, 026 , Ogun – 53,314 and the FCT 52,348 .

    The NPHCDA said those who have received their first shot, include health workers, frontline workers including; security agents, ports of entry staff, judiciary, petrol station workers, contingency workers and strategic leaders.

    It noted that some of the states went a step further to vaccinate willing pensioners, people aged 70 and above, teachers and journalists during the same period.

    The agency said that Lagos state was the only state that inoculated more than 200,000 residents during this first phase of vaccination in the country.

    The NPHCDA stated that states with lower inoculation are Bayelsa with 10, 751, Ebonyi – 9567 and Taraba- 9,334.

    It added that the Federal Government has directed states not to exceed the 50 per cent utilisation of the vaccines, to allow for a second dose to those who have taken their first.

    “The remaining 50 per cent reserved at the agency’s cold chain store will be administered eight to 12 weeks from the date of the first doses.

    “We have been careful to ensure that only those who are eligible to receive the COVID-19 vaccine in the current phase are being vaccinated,” it said.

    Meanwhile, the agency advised Nigerians to check their vaccination cards for their next appointment dates and where possible to try to go to the same health facilities where they got their initial dose for their second dose.

    It added that people who have received the first dose should not pre-register before going to the health facility for the second dose because they have already been capture.

    NAN report that Nigeria began COVID-19 vaccination on March 5 after receiving 3.94 million doses of the Oxford-AstraZeneca vaccine through COVAX, a UN-backed effort that promises access to free vaccines for up to 20 per cent of participating countries’ population.

    The country has received another 300,000 doses of the Astrazeneca vaccine from telecom giant, MTN and 100,000 doses of Covishield COVID-19 vaccines from the India government.

    Meanwhile, the Federal Government said the global scarcity of COVID-19 vaccines may delay the administration of the second dose.

    It said :’there is a global scarcity of COVID-19 vaccines due to high demand, especially in countries where they are being produced.

    “For this reason, we anticipate a delay in vaccine supply to Nigeria,” it said

  • Philippines lifts suspension on AstraZeneca vaccine for under 60

    Philippines lifts suspension on AstraZeneca vaccine for under 60

    The Philippines will resume administering AstraZeneca COVID-19 vaccine to people below 60 years of age, ending a temporary suspension over reports of rare blood clots in younger recipients overseas, health officials said on Monday.

    “The benefit outweighs the risk. Only a small percentage of the population had these adverse effects for AstraZeneca,” Health Undersecretary, Maria Rosario Vergeire, told a regular news conference, referring to countries where blood clots were reported.

    Health authorities will release guidelines, including different precautions on the use of the AstraZeneca shots, Vergeire added.

    The European Medicines Agency had earlier recommended including blood clots as a rare side effect of the AstraZeneca vaccine.

    The Southeast Asian nation is yet to record blood clots as side effect, but suspended the use of AstraZeneca’s vaccine for under 60s on April 8.

    The Philippines, a country of 108 million people, is battling one of the worst outbreaks in Asia but has administered less than 1.5 million shots of COVID-19 vaccines, 86 per cent of which were first doses.

    It has recorded 936,133 COVID-19 cases and 15,960 deaths due to the virus.

    The Philippines has received 525,600 doses of the AstraZeneca vaccine through the COVAX international vaccine-share facility.

    More than 900,000 more were to be shipped in May or June, according to health ministry data.

    Vaccines from China’s Sinovac Biotech accounts for 83 per cent of doses so far delivered to the Philippines.

  • My Vaccination Story – Azu Ishiekwene

    Azu Ishiekwene

    It wasn’t planned. I was seeing off my neighbour and friend on Thursday evening when one of the officers of our estate residents’ association called out to me.

    He was in knickers and shirtsleeves, with his right hand clutching his left shoulder. “I’ve just been vaccinated,” he said. “Would you like me to put your name forward for it tomorrow?”

    After what I have seen in the last one year – COVID-19 related deaths first becoming statistics, and then statistics becoming people, and people having faces, and faces becoming friends and relatives – news of the discovery of vaccines was a huge relief.

    After 56 years, health vulnerabilities and underlying conditions tend to increase. But confronting your mortality after that age also brings with it liberation from the fear of death. So, what’s all the fuss about the jab, anyway?

    But vaccines, like many good things, are made abroad, while rumours and myths about them are manufactured locally.

    Nigeria was expecting a consignment of about five million doses – one for every 40 citizens. With one of Africa’s highest infection and death rates at the height of the pandemic, no one was exactly sure how five million doses could work.

    One evening when I brought up the subject at home, with the enthusiasm of someone who had just discovered a magic formula, I noticed a pregnant look on my wife’s face. She suggested I asked the children what they think about vaccines before I decide on whether or not to take the shot when they became available.

    That made sense. Since the youngest of them is 21, I fully expected a robust conversation. But what I got on that conference call with two of them, obviously speaking for other family members, was more than robust: it was premeditated, full-blown vaccine rebellion.

    The chemical engineer, often the spokesperson, asked me what I knew about the vaccines already in circulation. This was in January. While a privileged few had either gone to Dubai to have it or, like the Governor’s wife, Ebele Obiano, chased it all the way down to Houston, Texas, for designer sessions, the bulk of us were just following the news.

    What do I know about the vaccines? I know they don’t offer 100 percent protection from Coronavirus infection and that they have been developed and are being deployed at a historically record speed. Initial data also suggested that with good hygiene and social protocols, vaccination could reduce the spread of the virus.

    My interlocutor laughed. Though conceding that science had done a great job of getting the vaccine out in record time, she said safety and efficacy may have been compromised on the altar of expediency and desperation.

    She said she was not sure that enough samples had been taken or time given to analyse the outcomes from the different population demographics before the vaccine rollout. She dived into the global vaccine politics between US and European pharma giants, and that between the west and China. Caution, Dad.

    And then she asked the mother of all questions: is there any evidence so far that a single particular vaccination could prevent the different strains popping up at the time or even if it does, where is the data that vaccination could prevent the risk of re-infection? Was I following what was happening in South Africa, for example?

    She summed it up by saying that for her, the risk of younger-not-obviously-at-risk persons taking the vaccination and being exposed to the potential negative side effects outweighed any benefits from taking any vaccination whose full after-effects were only just emerging.

    I disagreed. Of course, while I conceded that there was still more to learn about the safety and efficacy of the vaccines, my point was that on balance, it was better to risk staying alive by getting vaccinated than to risk infection, long-term impairment and possibly death, by abstaining based on groundless fears. And I don’t believe herd immunity is superior to personal responsibility.

    After 56 years, health vulnerabilities and underlying conditions tend to increase. But confronting your mortality after that age also brings with it liberation from the fear of death. So, what’s all the fuss about the jab, anyway?

    Strangely, throughout the conversation, my wife, otherwise an engaging, strongly-opinionated woman, was silent. We’re both above 50. After months of swallowing more than enough vitamins to float a chemist, immersing ourselves in steaming hot local herbs, and consuming all conceivable spices, I thought that this vaccination was our best chance to put the damn thing behind us once and for all; that we would be champions of vaccination.

    What’s more, in the midst of the second wave, my son had an infection scare that put him out of circulation for days and got me ringing up everyone I knew for advice! So, why won’t the family seize the opportunity for vaccination with both hands?

    The vaccine finally arrived in Nigeria in March, but the news didn’t lessen my isolation. A friend had shared with me a WhatsApp message about a tabular comparison of the safety, efficacy and unit prices of the four vaccines currently available – AstraZeneca, Pfizer, Moderna and Johnson & Johnson.

    Of the four, Pfizer was rated the most effective with 95 percent trial effectiveness and least side effects. At $20 per vial, it’s also the second most expensive. Moderna was 94 percent, pricier and with virtually the same side effects as Pfizer; while Johnson & Johnson and AstraZeneca, came in at 66.9 percent and 62 percent effectiveness respectively with longer lists of side effects.

    Others may think of AstraZeneca as the redeeming vial of the world’s majority, and Nigeria may be congratulating itself that it’s not too far behind in importing a limited quantity but the fact that AstraZeneca is in the bottom of the pile – the cheapest of the lot and the worst for side effects – seemed to highlight, if not confirm, my daughter’s worst suspicions.

    My family already rebelling against vaccination, was hardly in the mood for AstraZeneca. Their suspicions were compounded by anxiety about all that could go wrong in the supply chain from shipment abroad, through many potentially crooked paths, to the point where the jab is taken. How do you even know what you’re getting and if – or when – the next dose will come?

    These images flooded my mind on Thursday when my neighbour offered to enroll me for AstraZeneca in the estate. If I had been offered a chance at self-assisted suicide, I would not have felt more conflicted.

    “Why are you looking at me like that”, my neighbour asked. “Are you not interested? The medical team will be in the estate again by 8am on Friday. Let me have your name and your wife’s name, too.”

    I snapped out of my confusion. “Leave my wife out,” I said. “Put my name down. I will be there at eight in the morning to take the shot.”

    That night, my wife convened another family conference. She called the children, one by one, to inform them that I had decided to take the vaccine. The chemical engineer was at her hilarious, even mischievous, best. She asked if I had written my Will and who was my next of kin. She also asked if I had left my bank details and details of any other valuables within reach.

    As for herself, she said, even though there was a little more data about the vaccines today than was available in January, the risk of the unknown was still troubling.

    We laughed and talked through it again and I went to bed asking myself, what if she’s right? Too bad, too late. My mind was made up. I’ll take the vaccine.

    I turned up at the initial vaccination venue in the estate as Number 200 on the list. I learnt that over 80 persons had been vaccinated the previous day and there were no adverse reports. Today, persons of various ages – a good number of them 60 and above – were on the queue. With 199 persons ahead of me, whatever happened, I was in good company.

    The venue was later changed but I stuck with the train and after re-numbering came up at 37. After three hours’ wait, I took my jab and went home.

    From the moment I walked in, my wife’s eyes were on me. She asked if I felt anything, I said I didn’t, which was true. She fussed that I should immediately use analgesics, but I brushed her suggestion aside. My children called and took turns to pepper and tease me with questions about how I was feeling. I told them I felt nothing, which again, was true.

    I have heard of stories of nausea, of dizziness, pains or aches after vaccination, but experienced nothing of the sorts.

    I went to bed and slept like a log. I woke up hale and hearty. It’s been one week since, and I’m not growing horns. Three days after I took my shot, when my wife was sure I was alive, she lined up for her shot, too!

    Then after she took it, I reminded her that the book says the second shot should come 15 to 22 days after the first shot, but our next appointment is in June, nearly three months after our first shot! I’m not living worried, especially since I’m now even in better company than when I lined up for my dose.

    The family’s guinea pig is in excellent company, at last. And yet, it was not planned.

     

    Ishiekwene is the Editor-In-Chief of LEADERSHIP

     

  • France probes death of student who got AstraZeneca jab

    France probes death of student who got AstraZeneca jab

    French authorities said Tuesday they were investigating the death of a 26-year-old medical student days after he received AstraZeneca‘s COVID-19 vaccine, while stressing that no link had been established yet with the jab.

    The student died on March 18 in the western city of Nantes, 10 days after receiving the AstraZeneca jab.

    The public prosecutor in Nantes, Pierre Sennes, said that an autopsy had been carried out on him a day after his death but that “it was necessary to carry out further tests to determine the causes and circumstances of his death”.

    The ANSM national drug safety watchdog said it had been informed of the man’s death “as part of our increased monitoring of thrombosis cases” and said for the moment there was no clear link with the inoculation.

    “This death is the subject of an in-depth clinical investigation,” it said in a statement, giving the student’s age as 24. The prosecutor’s office said later he was aged 26.

    News of the man’s death came five days after France and several other countries resumed AstraZeneca vaccinations after having briefly suspended it over reports of blood clots in a small number some people who received the jab.

    France’s medicines regulator recommends the vaccine for those aged 55 and over as the reports of blood clots have been in those aged younger.

    The vaccine has been backed by the World Health Organization and the EU’s drugs regulator, which have said there was no evidence of a link to an increased risk of blood clots.

    The WHO said reported rates of so-called thromboembolic events after COVID-19 vaccines were in line with the usual number of people suffering these conditions.

  • COVID-19: About 122,000 persons get AstraZeneca vaccines

    COVID-19: About 122,000 persons get AstraZeneca vaccines

    The Presidential Task Force (PTF) on COVID-19 said about 122,410 persons have been vaccinated with the AstraZeneca vaccines.

    Dr Faisal Shuaib, the Executive Director, National Primary Health Care Development Agency ((NPHCDA), said this while speaking at the National PTF briefing on Monday in Abuja.

    Shuaib said only Kogi, Kebbi, Zamfara and Oyo States were yet to officially kicked-off vaccination.

    He, however, said Oyo state was set to commence any moment as there were indications that the state could start vaccination on Monday.

    On reservations against AstraZeneca vaccines, he said a study in the U.S had showed that no cases of blood clot and the vaccine was fully safe and efficacious.

    “Recently, there have been concerns raised on the safety and efficacy of the Oxford AstraZeneca vaccine.

    ”The European Medicines Agency has declared the Oxford organic COVID-19 vaccine as safe and efficacious after an investigation that was conducted in two cases of adverse events of blood clotting alleged to have been linked to the batch of the vaccine in some European countries,” he said.

    Shuaib said that from the long awaited U.S trial of the vaccine confirmed that it was both safe and highly effective.

    He added that it was probably the most effective stopping symptomatic COVID-19.

    Shuaib said that it was about 100 per cent effective at preventing serious illness, adding that the study also showed no issue regarding blood clots.

    On the reported cases of bribe for vaccine at Falamo, Lagos State, Shuaib said: “We expect full accountability of vaccines given in states and the reported cases of fraud in Falamo, Lagos state, was being investigated.

    “We will ensure that anybody that is indicted in the case is dealt with in accordance with the law.

    “On this issue, the PTF is closely monitoring vaccine accountability all across the country in order to ensure that similar activities of vaccine management and other sharp practices are avoided.

    ”We have also established a collaborative partnership with regulatory and anti-corruption agencies to further strengthen vaccine accountability.”

  • NAFDAC sends important message to Nigerians over COVID-19 vaccine labels

    NAFDAC sends important message to Nigerians over COVID-19 vaccine labels

    The National Agency for Food and Drug Administration and Control (NAFDAC), has advised Nigerians to ensure the Astrazeneca vaccine being administered on them had the original label.

    The agency said the warning was imperative to ensure people did not risk being vaccinated with fake Astrazeneca vaccine.

    The position of NAFDAC is contained in a statement signed by the agency’s Director General, Prof. Mojisola Adeyeye, on Sunday, in Abuja.

    Adeyeye, explained that the original Oxford Astrazeneca University (AZOU) vaccine, had been contracted to India’s world largest vaccine manufacturer, Serum Institute of India (SIIPL), to produce in large quantity.

    “AZOU gave the license of its vaccine to Serum Institute of India PVT Ltd, (SIIPL), to manufacture this vaccine at a commercial scale. SIIPL is the largest vaccine manufacturer in the world and the company got the license by signing the manufacturing agreement.

    “SIIPL gave the vaccine the trade name COVISHIELD, it is the result of a cooperation and a technology transfer from AstraZeneca – University of Oxford to SIIPL.

    “SIIPL is now the world’s largest vaccine manufacturer by number of doses produced and sold globally.

    “More than 1.5 billion doses, which include Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella,” she said.

    Adeyeye added that the vaccines manufactured by SIIPL were accredited by the World Health Organisation (WHO), and were being used in about 170 countries across the globe in their national immunisation programme.

    She added that both COVISHIELD manufactured by SIIPL and COVID-19 vaccine Astrazeneca, manufactured by Astrazeneca/Oxford University vaccine are the same vaccine.

    According to Adeyeye, ChAdOx1 nCoV- 19 corona virus vaccines (Recombinant), COVISHIELD, was granted Emergency Use Listing (EUL) by the World Health Organisation on Feb.15, and that it was one of the listed vaccines under the COVAX Facility.

  • Denmark reports two cases of serious illness, one death after AstraZeneca shot

    Denmark reports two cases of serious illness, one death after AstraZeneca shot

    Denmark said on Saturday that one person had died and another fell seriously ill with blood clots and cerebral haemorrhage after receiving the AstraZeneca COVID-19 vaccination.

    The two, both hospital staff members, had received the AstraZeneca vaccine less than 14 days before getting ill, the authority that runs public hospitals in Copenhagen said.

    The Danish Medicines Agency confirmed it had received two “serious reports”, without giving further details.

    There were no details of when the hospital staff got ill.

    Denmark, which halted using the AstraZeneca vaccine on March 11, was among more than a dozen countries that temporarily paused the use of the vaccine after reports of cases of rare brain blood clots sent scientists and governments scrambling to determine any link.

    Some countries, including Germany and France, this week reversed their decision to suspend the use of the vaccine following an investigation into the reports of blood clots by the European Union’s drug watchdog.

    EU said, on Thursday, it is still convinced the benefits of the vaccine outweigh the risks.

    Denmark – along with Sweden and Norway – said on Friday it needed more time to decide whether to use the vaccine.

    “We prioritise reports of suspected serious side effects such as these and examine them thoroughly to assess whether there is a possible link to the vaccine,’’ Tanja Erichsen, acting Director of Pharmacovigilance at the Danish Medicines Agency, said in a tweet on Saturday.

    “We are in the process of dealing with the two specific cases.’’

    European Medicines Agency (EMA) Director, Emer Cooke said on Thursday the watchdog could not definitively rule out a link between blood clot incidents and the vaccine in its investigation into 30 cases of a rare blood clotting condition.

    But she said the “clear” conclusion of the review was that the benefits in protecting people from the risk of death or hospitalisation outweigh the possible risks.

    The issue deserves further analysis, the EMA said.

    AstraZeneca, which developed the shot with Oxford University, said that a review, covering more than 17 million people who had received its shots in the EU and Britain, had found no evidence of an increased risk of blood clots.

    The company on Saturday declined to comment on the new cases in Denmark but referred to a statement published on Thursday, in which its Chief Medical Officer, Ann Taylor, said: “Vaccine safety is paramount and we welcome the regulators’ decisions which affirm the overwhelming benefit of our vaccine in stopping the pandemic.

    “We trust that, after the regulators’ careful decisions, vaccinations can once again resume across Europe’’.